261 related articles for article (PubMed ID: 33606537)
1. Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2.
Liu Z; Hu X; Wang Q; Wu X; Zhang Q; Wei W; Su X; He H; Zhou S; Hu R; Ye T; Zhu Y; Wang N; Yu L
J Med Chem; 2021 Mar; 64(5):2829-2848. PubMed ID: 33606537
[TBL] [Abstract][Full Text] [Related]
2. EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex.
Hsu JH; Rasmusson T; Robinson J; Pachl F; Read J; Kawatkar S; O' Donovan DH; Bagal S; Code E; Rawlins P; Argyrou A; Tomlinson R; Gao N; Zhu X; Chiarparin E; Jacques K; Shen M; Woods H; Bednarski E; Wilson DM; Drew L; Castaldi MP; Fawell S; Bloecher A
Cell Chem Biol; 2020 Jan; 27(1):41-46.e17. PubMed ID: 31786184
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and evaluation of EZH2-based PROTACs targeting PRC2 complex in lymphoma.
Xie H; Xu W; Liang J; Liu Y; Zhuo C; Zou X; Luo W; Xiao J; Lin Y; Chen L; Li H
Bioorg Chem; 2023 Nov; 140():106762. PubMed ID: 37572533
[TBL] [Abstract][Full Text] [Related]
4. A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination.
Wang X; Cao W; Zhang J; Yan M; Xu Q; Wu X; Wan L; Zhang Z; Zhang C; Qin X; Xiao M; Ye D; Liu Y; Han Z; Wang S; Mao L; Wei W; Chen W
EMBO J; 2017 May; 36(9):1243-1260. PubMed ID: 28320739
[TBL] [Abstract][Full Text] [Related]
5. Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020).
Dockerill M; Gregson C; O' Donovan DH
Expert Opin Ther Pat; 2021 Feb; 31(2):119-135. PubMed ID: 33103538
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel pyridone-benzamide derivatives possessing a 1-methyl-2-benzimidazolinone moiety as potent EZH2 inhibitors for the treatment of B-cell lymphomas.
Wu D; Zeng X; Zhao Y; Qin M; Gong P
Bioorg Med Chem; 2024 May; 105():117725. PubMed ID: 38640588
[TBL] [Abstract][Full Text] [Related]
7. Targeting EZH2 as cancer therapy.
Hanaki S; Shimada M
J Biochem; 2021 Sep; 170(1):1-4. PubMed ID: 33479735
[TBL] [Abstract][Full Text] [Related]
8. Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.
Zhao Y; Guan YY; Zhao F; Yu T; Zhang SJ; Zhang YZ; Duan YC; Zhou XL
Eur J Med Chem; 2022 Mar; 231():114144. PubMed ID: 35093670
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel EZH2 inhibitors through pharmacophore-based virtual screening and biological assays.
Wu Y; Hu J; Ding H; Chen L; Zhang Y; Liu R; Xu P; Du D; Lu W; Liu J; Liu Y; Liu YC; Lu J; Zhang J; Yao Z; Luo C
Bioorg Med Chem Lett; 2016 Aug; 26(15):3813-7. PubMed ID: 27289323
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and activity evaluation of quinolinone derivatives as EZH2 inhibitors.
Cai J; You H; Qin X; Wang Y; Li W
Bioorg Med Chem Lett; 2024 Jun; 105():129726. PubMed ID: 38580135
[TBL] [Abstract][Full Text] [Related]
11. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer.
Kim W; Bird GH; Neff T; Guo G; Kerenyi MA; Walensky LD; Orkin SH
Nat Chem Biol; 2013 Oct; 9(10):643-50. PubMed ID: 23974116
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a first-in-class EZH2 selective degrader.
Ma A; Stratikopoulos E; Park KS; Wei J; Martin TC; Yang X; Schwarz M; Leshchenko V; Rialdi A; Dale B; Lagana A; Guccione E; Parekh S; Parsons R; Jin J
Nat Chem Biol; 2020 Feb; 16(2):214-222. PubMed ID: 31819273
[TBL] [Abstract][Full Text] [Related]
13. Proteolysis Targeting Chimera (PROTAC) for Macrophage Migration Inhibitory Factor (MIF) Has Anti-Proliferative Activity in Lung Cancer Cells.
Xiao Z; Song S; Chen D; van Merkerk R; van der Wouden PE; Cool RH; Quax WJ; Poelarends GJ; Melgert BN; Dekker FJ
Angew Chem Int Ed Engl; 2021 Aug; 60(32):17514-17521. PubMed ID: 34018657
[TBL] [Abstract][Full Text] [Related]
14. Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader.
Potjewyd F; Turner AW; Beri J; Rectenwald JM; Norris-Drouin JL; Cholensky SH; Margolis DM; Pearce KH; Herring LE; James LI
Cell Chem Biol; 2020 Jan; 27(1):47-56.e15. PubMed ID: 31831267
[TBL] [Abstract][Full Text] [Related]
15. Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2-EED Interaction.
Du D; Xu D; Zhu L; Stazi G; Zwergel C; Liu Y; Luo Z; Li Y; Zhang Y; Zhu K; Ding Y; Liu J; Fan S; Zhao K; Zhang N; Kong X; Jiang H; Chen K; Zhao K; Valente S; Min J; Duan W; Luo C
J Med Chem; 2021 Jun; 64(12):8194-8207. PubMed ID: 34077206
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma.
Tu Y; Sun Y; Qiao S; Luo Y; Liu P; Jiang ZX; Hu Y; Wang Z; Huang P; Wen S
J Med Chem; 2021 Jul; 64(14):10167-10184. PubMed ID: 34196564
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer.
Song X; Gao T; Wang N; Feng Q; You X; Ye T; Lei Q; Zhu Y; Xiong M; Xia Y; Yang F; Shi Y; Wei Y; Zhang L; Yu L
Sci Rep; 2016 Feb; 6():20864. PubMed ID: 26868841
[TBL] [Abstract][Full Text] [Related]
18. Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.
Honma D; Kanno O; Watanabe J; Kinoshita J; Hirasawa M; Nosaka E; Shiroishi M; Takizawa T; Yasumatsu I; Horiuchi T; Nakao A; Suzuki K; Yamasaki T; Nakajima K; Hayakawa M; Yamazaki T; Yadav AS; Adachi N
Cancer Sci; 2017 Oct; 108(10):2069-2078. PubMed ID: 28741798
[TBL] [Abstract][Full Text] [Related]
19. AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition.
Zhang KL; Shen QQ; Fang YF; Sun YM; Ding J; Chen Y
Acta Pharmacol Sin; 2019 Dec; 40(12):1587-1595. PubMed ID: 31171828
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of (E)-1,2-diphenylethene-based EZH2 inhibitors.
He H; Hu X; Teng F; Liu Z; Zhang Q; Feng Z; Feng Q; Yu L
Bioorg Med Chem Lett; 2020 Mar; 30(5):126957. PubMed ID: 31959420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
